The first country to register Sputnik V for public use in August sees that the vaccine is 92% effective at protecting people from COVID-19 according to interim trial results. The country’s sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.
The initial results are only the second to be published from a late-stage human trial in the global race to produce a vaccine that could halt a pandemic that has killed more than 1.2 million people and ravaged the world economy.
The interim results are based on data from the first 16,000 trial participants to receive both shots of the two-dose vaccine, the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, said.
The so-called Phase III trial of the shot developed by the Gamaleya Institute is taking place in 29 clinics across Moscow and will involve 40,000 volunteers in total, with a quarter receiving a placebo shot.
The chances of contracting COVID-19 were 92% lower among people vaccinated with Sputnik V than those who received the placebo, the RDIF said.
That’s well above the 50% effectiveness threshold for COVID-19 vaccines set by the U.S. Food and Drug Administration.
1 Comment
Hi there, You’ve done an incredible job. I’ll certainly
digg it and perssonally sugest tto my friends.
I’m confident tthey will be benefited from this site. https://Glassi-Info.Blogspot.com/2025/08/deposits-and-withdrawals-methods-in.html